Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight,
hunger assessments and other factors in patients with rare genetic disorders of obesity.